Frazier Life Sciences

Frazier Life Sciences Frazier Life Sciences is a Palo Alto-based firm that has raised $3.6B+ across 5 venture funds since 2016. Fund XII, at $1.3B (2025), is the largest to date and targets company creation and early-stage biopharmaceutical investment. Portfolio companies have produced 40+ FDA-approved therapeutics since 2010. Notable exits include Chinook Therapeutics ($3.5B acquisition by Novartis) and Alpine Immune Sciences ($4.9B acquisition by Vertex). The firm has a strong oncology focus t